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Abstract
Alcoholic liver disease (ALD) due to chronic alcohol consumption is a significant 
global disease burden and a leading cause of mortality. Alcohol abuse induces a 
myriad of aberrant changes in hepatocytes at both the cellular and molecular 
level. Although the disease spectrum of ALD is widely recognized, the precise 
triggers for disease progression are still to be fully elucidated. Oxidative stress, 
mitochondrial dysfunction, gut dysbiosis and altered immune system response 
plays an important role in disease pathogenesis, triggering the activation of 
inflammatory pathways and apoptosis. Despite many recent clinical studies 
treatment options for ALD are limited, especially at the alcoholic hepatitis stage. 
We have therefore reviewed some of the key pathways involved in the patho-
genesis of ALD and highlighted current trials for treating patients.
Key Words: Liver; Alcohol; Oxidative stress; Inflammation; Gut microbiome; Mitochon-
dria
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: Alcoholic liver disease (ALD) causes significant global disease burden indu-
cing both cellular and molecular modifications in hepatocytes. Although the spectrum 
of disease is widely recognized, the precise disease pathogenesis is yet to be fully 
elucidated. In this review we summarize some of the key pathways responsible for the 
pathogenesis of ALD and highlight current available treatments.
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Alcoholic liver disease (ALD) is one of the most prevalent chronic liver diseases and 
causes significant mortality globally. Chronic alcohol consumption has been imp-
licated in multiple medical conditions including cancer, diabetes, cardiovascular 
disease, liver and pancreatic disorders. However, no new treatment options have been 
developed for many years. At present, abstinence remains the most important treat-
ment for ALD, however, there is a need to develop effective treatment options asso-
ciated with alcohol misuse.
The spectrum of ALD is widely recognized ranging from simple liver steatosis; 
which can occur in up to 90% of heavy drinkers[1] to alcoholic hepatitis (AH), which 
develops in 10% to 35% of heavy drinkers[2]. AH can ultimately progress to fibrosis, 
where hepatic stellate cell (HSC) activation, collagen synthesis and accumulation of 
extracellular matrix proteins occurs due to the formation of protein adducts. Cirrhosis 
and lastly hepatocellular cancer are the final stages. Fibrosis/cirrhosis can cause 
hepatocyte inactivation, and is associated with abnormal DNA repair, damage to 
mitochondrial function and oxygen utilization disorders[3]. This can lead to hepato-
cellular failure and portal hypertension which ultimately requires a liver transplan-
tation.
The molecular and biochemical mechanisms underlying the pathogenesis of ALD as 
well as the precise triggers for disease progression are not completely understood. 
Recent evidence suggests disease progression is thought to involve several patho-
logical stages such as mitochondrial dysfunction, oxidative stress, altered methionine 
metabolism, iron dysregulation, gut dysbiosis, activation of inflammatory pathways 
and decreased production of antioxidants (Figure 1)[4]. Currently, no effective treat-
ment for ALD exists due to the incomplete understanding of hepatic biochemical 
alterations and pathogenic mechanisms responsible for disease progression.
EPIDEMIOLOGY AND PREVALENCE
Alcohol misuse is a leading cause of liver disease worldwide. ALD is a global disease 
burden and results in approximately 3 million deaths per year[5]. In 2016, 5.3% of all 
deaths were caused by the harmful effects of alcohol worldwide[5]. Alcohol accounts 
for 5.1% of total disease burden worldwide, measured in disability-adjusted life years
[5]. Total alcohol consumption per capita increased in 2005 from 5.5 L to 6.4 L in 2010 
and was sustained at 6.4 L in 2016[5]. Europe has the highest per capita alcohol 
consumption and disability-adjusted life years[5], as well as binge drinking partic-
ularly, in France and England[6].
Although the overall prevalence of ALD has remained stable from 2001-2016 at 
between 8.1%-8.8%, the proportion of ALD with stage 3 fibrosis and above has 
increased from 2.2%-6.6%[7], such that in the United States chronic liver disease and 
cirrhosis is the 12th leading cause of death[7]. In the United States, the number of adults 
listed as waiting for liver transplants also increased by 63% from 2007 to 2017[7], 
where approximately one third of all liver transplants are due to alcohol-related 
disease[8]. Due to the high-risk drinking rates, the number of deaths due to alcohol-
related liver disease in the United States is projected to increase by 84% from 2019-2040
[9]. In the United Kingdom, the number of deaths from ALD was reported at 5964 
deaths in 2020 compared to 4954 deaths in 2019, increasing by 20%[10]. From 2001 the 
number of deaths due to ALD has increased by 72% from 2001-2020[10].
There are several factors which effect the development of ALD. There are significant 
differences in the amounts of alcohol consumed between males and females. It is well 
documented that men consume more alcohol than women, leading to a higher pre-
valence of alcohol related liver disease[11]. It is estimated 237 million men and 46 
million women have alcohol use disorders[5]. Although men often consume more 
alcohol, women are more susceptible to the toxic effects of alcohol and have a higher 
risk of advanced liver disease[11], due to higher blood alcohol concentrations despite 
equal dosing between genders[11]. Therefore, female gender is an important risk factor 
for progression of ALD. Genomic data has also discovered that a variation in the 
PNPLA3 gene is associated with increased hepatic fat content, increasing the risk of 
both ALD and non-alcoholic fatty liver disease, which has the highest frequency in 
Hispanics[12].
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Figure 1 Alcohol-related induction of oxidative stress and liver injury. Alcohol misuse leads to loss of tight junctions in the gut increasing its 
permeability. This causes translocation of lipopolysaccharide into the liver activating toll-like receptor 4 on Kupffer cells (KCs). Activation of KCs can cause reactive 
oxygen species (ROS) production and pro-inflammatory cytokines such as tumor necrosis factor-α. ROS production also occurs due to the metabolism of alcohol. 
ROS production and inflammatory cytokines leads to inflammation and recruitment of inflammatory cells as well as activation of apoptotic pathways. (Figure created 
with BioRender.com). LPS: Lipopolysaccharide; ROS: Reactive oxygen species; TNF-α: Tumor necrosis factor-α.
DISEASE SPECTRUM
Sustained excessive alcohol consumption produces a vast range of hepatic lesions. The 
first stage is liver steatosis or alcoholic fatty liver, which can occur in up to 90% of 
heavy drinkers, emerging as early as 3 to 7 d after initial excessive alcohol consump-
tion[1]. Steatosis is often asymptomatic with normal or only slightly increased liver 
enzymes levels. The deposition of microscopic fat droplets occurs initially in the 
centrilobular zone then spreads towards the periportal region of hepatocytes[13]. 
Steatosis, although reversible and originally thought to be a benign state, is a now a 
priming phase for AH, which develops in 10% to 35% of heavy drinkers and is a more 
severe stage of ALD. AH is characterized by hepatocyte ballooning, the formation of 
Mallory-Denk bodies, infiltration of white blood cells, Kupffer cell (KC) activation, and 
collagen deposition via once dormant HSCs[14], the latter playing an important role in 
fibrosis leading to cirrhosis. At this stage hepatocyte inactivation, abnormal DNA 
repair, damage to mitochondrial structures, oxygen utilization disorders, and the 
accumulation of extracellular matrix proteins occurs[3]. Continuation of hepatic 
scarring and the spread of collagen (bridging fibrosis) throughout the liver can lead to 
cirrhosis and in some cases hepatocellular cancer.
Although the pathogenesis of ALD is yet to be fully understood, it is thought to 
include multiple interplaying factors and pathways including the production of toxic 
ethanol metabolites, oxidative stress, innate and adaptive immune activation, fi-
brogenesis and cell death. Upon activation of these pathways tissue damage can occur 
leading to the progression of the disease. This review will focus on mechanisms 
involved in inflammation that predominantly occur at the AH stage.
ALCOHOL METABOLISM
Within the liver, alcohol dehydrogenase and cytochrome p450 2E1 (CYP2E1) are the 
main oxidative pathways of alcohol metabolism. Another minor pathway of alcohol 
metabolism in the liver is via the peroxisomal enzyme catalase[15]. A small proportion 
of ethanol may also be metabolized by non-oxidative pathways such as by interaction 
with fatty acids, generating fatty acid ethyl esters[16]. Alcohol dehydrogenase oxi-
datively metabolizes alcohol to acetaldehyde, a highly reactive and toxic by product 
that contributes to tissue damage. This conversion reaction requires the cofactor nicoti-
namide adenine dinucleotide (NAD+), creating reduced NAD+ in the process. Due to 
the toxic nature of acetaldehyde, it is further oxidized to acetate, catalyzed by the 
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enzyme mitochondrial aldehyde dehydrogenase-2[17]. Increased conversion of NAD+ 
results in leakage of electrons and reactive oxygen species (ROS) production. The toxic 
metabolites produced during alcohol metabolism as well as increased ROS can also 
trigger endoplasmic reticulum (ER) stress. The second major pathway is via the 
microsomal ethanol-oxidizing system and involves CYP2E1, which is involved in 
ethanol oxidation to acetaldehyde[17]. The activity of CYP2E1 is induced by alcohol, 
increasing its hepatocellular content causing accumulation of CYP2E1[18]. Electron 
leakage from the CYP2E1 pathway, leads to ROS generation, including hydroxyethyl, 
superoxide anion and hydroxyl radicals[19]. ROS can also form lipid peroxides and 
DNA adducts such as N2-ethyldeoxyguanosine, which has been detected both in the 
livers of alcohol-fed rats as well as leukocytes in ALD patients[20].
AUTOPHAGY, MITOPHAGY AND INFLAMMASOMES
Alcohol metabolism increases ROS production and ER stress leading to calcium 
depletion, glycosylation and lipid overloading, triggering the unfolded protein res-
ponse (UPR)[21]. The UPR can restore ER homeostasis by attenuating translation of 
proteins, increasing folding capacity and degrading unfolded proteins. However, a 
prolonged UPR causes inflammation, fat accumulation, mitochondrial stress and 
apoptosis via direct activation apoptosis signal-regulating kinase 1[22], nuclear factor-
κB (NF-κB), c-Jun N-terminal kinases and P38[23]. Alcohol induced ER stress invol-
ving an impaired UPR was first identified in a model of intragastric alcohol fed mice
[24].
Alcohol can induce autophagy, a self-degradative process which occurs by the 
action of lysosomes and can be selective only for damaged mitochondria (mitophagy). 
Evidence suggests that autophagy in ALD can have inhibitory effects on inflammation 
and steatosis as well as the ability to remove lipid droplets, Mallory-Denk bodies and 
damaged mitochondria[25]. Whilst tumor necrosis factor (TNF)-α induces autophagy, 
generation of ROS can lead to inhibition of TNF-α induced autophagy through 
activation of NF-κB[26]. This suggests dysfunction of autophagy is associated with 
ALD pathogenesis[27,28]. Multiple animal models have observed autophagy as a 
protective response in ALD, as well as confirming ameliorative effects in ALD. Acute 
ethanol feeding (6 g/kg bodyweight) increased autophagy as measured by autopha-
gosome numbers, however, chronic ethanol feeding (5.2% ethanol by volume) 
inhibited hepatic autophagy[29], suggesting that this protective mechanism is lost with 
longer term alcohol consumption.
Mitophagy can also be induced as a protective response to both acute and chronic 
alcohol consumption due to accumulation of ROS or loss of mitochondrial membrane 
potential via elimination of dysfunctional mitochondria. The process of mitophagy 
depends on induction of autophagy and priming of damaged mitochondria for re-
cognition and is mediated by phosphatase and tensin homolog-induced putative 
kinase 1-Parkin signalling pathway or Nip3-like protein X[30]. The duration of alcohol 
exposure can affect the mitophagy process[30]. In rats, binge-models of alcohol 
consumption have been shown to increase mitophagy, decreasing alcohol-induced 
hepatoxicity[30,31]. Acute ethanol consumption also increases transcription factor EB, 
a master regulator of lysosomal biogenesis, however, chronic ethanol exposure de-
creased transcription factor EB[29]. Accumulation of damaged mitochondria occurs in 
chronic ethanol models which releases mitochondrial damage-associated molecular 
patterns (DAMPs), which in turn promote inflammation and fibrogenesis contributing 
to accelerated disease state[30]. Mitochondrial DNA (a mitochondrial DAMP), can 
bind to toll-like receptor (TLR)-9 activating HSCs and fibrogenesis[31]. Therefore, 
targeting mitophagy may be a potential therapeutic for ALD.
Inflammasomes
Oxidative stress in response to alcohol metabolism can damage hepatocytes, releasing 
endogenous DAMPs. Recognition of DAMPs can induce inflammation by release of 
proinflammatory cytokines, immune cell localization and stimulation of the inflam-
masome[32]. Inflammasomes are expressed in hepatic cells and are multi-protein 
complex’s containing a nucleotide-binding oligomerization domain-like receptor 
(NLR). Inflammasome activation is thought to be a two-step process. Inflammasome 
sensor molecules can trigger the assembly of inflammasomes, including NLR mole-
cules, for example NOD-, LRR- and pyrin domain-containing 3 (NLRP3)[33]. Assem-
bly is initiated by TLR and pathogen-associated molecular pattern (PAMP)/DAMP 
signaling which results in the NLR forming complexes with pro-caspase 1 with or 
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without an adaptor molecule, apoptosis-associated speck like CARD-domain contai-
ning protein (ASC)[4,33]. Inflammasome assembly initiates cleavage of procaspase-1 to 
its active form caspase-1. Activated caspase-1 then promotes the secretion and ac-
tivation of pro-inflammatory cytokines via cleavage of pro-interleukin (IL)-1β and pro-
IL-18 into their active forms IL-1β and IL-18[33]. IL-1β plays an important role in the 
infiltration of immune cells and IL-18 is important for the production interferon-
gamma (IFN-γ)[33]. Inflammasome activation also leads to a pathway of cell death 
called pyroptosis.
NLRP3 can be activated by a variety of stimuli including bacterial toxins, mito-
chondrial dysfunction and production of ROS. Interestingly, increased levels of IL-1β, 
ASC and NLRP3 have been documented in the livers of ethanol fed mice, whereas 
elevated mRNA expression of IL-1β, IL-18 and caspase-1 has been documented in the 
liver of ALD patients which correlated with liver lesions[34] and has also been 
associated with the development of liver fibrosis. Blocking IL-1β activity strongly 
decreases liver inflammation and damage[35]. Higher levels of serum IL-1 has also 
been documented in patients with AH in comparison to healthy controls[36]. Caspase-
1 knockout mice have also been shown to be protected from fibrosis as well as treat-
ment with IL-1 receptor antagonist has been shown to attenuate steatosis and liver 
injury when administered 2 wk post-ethanol feeding[36]. Decreased inflammation, 
steatosis and IL-1β expression has been associated in NLRP3 deficiency. Research has 
also shown mice deficient in NLRP3 have protection against ethanol-induced inflam-
mation including attenuation of steatosis and liver injury[37]. Previous research has 
also shown inflammasome components such as NLRP3 and ASC are present in HSCs 
and are required for the development of liver fibrosis by inducing changes including 
upregulation of transforming growth factor-β and collagen[38]. Therefore, this 
demonstrates the importance of IL-1β signaling, inflammasome components and 
activation in ALD.
INNATE AND ADAPTIVE IMMUNITY
Gut permeability
Increases in gut permeability due to alcohol has been confirmed in both clinical and 
experimental studies[39,40]. Increased gut permeability enables the entrance of 
PAMPs, such as lipopolysaccharide (LPS) in the portal circulation[41]. LPS is one of 
the exogenous ligands for TLR4, a pattern recognition receptor found on KCs. LPS 
interaction with TLR4 initiates downstream signaling via TIR-domain-containing 
adapter-inducing IFN-β and IFN regulatory factor 3, leading to production of 
proinflammatory cytokines proinflammatory cytokines such as TNF-α and IL-1β 
(Figure 2), the former can activate the extrinsic pathway of apoptosis via the TNF 
receptor 1 and TNF receptor 2 signaling[42]. High levels of these death receptors, 
including Fas, are expressed in all liver cells, therefore, the extrinsic pathway is the 
main apoptotic pathway in hepatocytes, such that hepatocyte apoptosis has been 
correlated with severity of disease in AH[43]. Serum TNF-α and IL-6 are also increased 
after exposure to alcohol and LPS[44], with TNF-α correlating with liver injury and 
mortality. However, chronic ethanol exposure to TNF-α knockout mice does not cause 
alcohol-associated inflammation and liver injury[45], therefore, mechanisms to reduce 
TNF-α may be an important tool in preventing inflammation.
Natural killer cells
LPS and HSCs can directly interact with immune cells such as natural killer (NK) cells, 
natural killer T (NKT) cells and T cells leading to disease progression[46]. NK cells can 
kill activated HSCs via TNF-α related apoptosis, however, HSCs isolated from ethanol-
fed mice showed reduced sensitivity to NK cell killing[46]. Alcohol consumption also 
enhances splenic NK cell apoptosis and blocks NK cell release from the bone marrow, 
as well as accelerating progression to fibrosis due to reduced NK cell activity[46]. Gut-
derived bacteria such as LPS may influence the activation of hepatic NKT cells leading 
to induction of HSCs and apoptosis, further exacerbating liver injury. Patients with 
ALD have shown a decreased number of circulating NK cells along with reduced 
cytotoxic activity resulting in decreased anti-viral, anti-fibrotic, and anti-tumor effects 
which can contribute to accelerated progression of disease state[47]. However, NK/ 
NKT cells may inhibit fibrosis through deletion of activated HSCs and production of 
IFN-γ[48]. On the other hand, activation of NKT cells also promotes liver fibrosis via 
enhancing hepatocellular damage and promoting HSC activation[48]. Therefore, a 
balance is required between inhibitory and stimulatory effects for liver health.
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Figure 2 The inflammatory response during alcoholic liver disease. Excessive consumption of alcohol causes lipopolysaccharide release from the gut 
activating toll-like receptor 4 on Kupffer cells (KCs). Pattern recognition receptors become activated by pathogen-associated molecular patterns/damage-associated 
molecular patterns which induces inflammation via release of proinflammatory cytokines and inflammasome activation. Interleukin (IL)-18 production from KCs causes 
activation of natural killer cells. Toll-like receptor stimulation in hepatic stellate cells results in the expression of IL-6, transforming growth factor-β1 and tumor necrosis 
factor-α. (Figure created with BioRender.com). DAMPs: Damage-associated molecular patterns; FFA: Free fatty acids; PAMPs: Pathogen-associated molecular 
patterns; IL: Interleukin; LPS: Lipopolysaccharide; NF-κB: Nuclear factor-κB; NK: Natural killer; NLRP3: NOD-, LRR- and pyrin domain-containing protein 3; PRR: 
Pattern recognition receptor; ROS: Reactive oxygen species; TGF-β: Transforming growth factor β; TLR4: Toll-like receptor 4; TNF-α: Tumor necrosis factor-α.
Neutrophil activation
Neutrophils can be recruited in response to liver injury to form neutrophil extracel-
lular traps (NETs), which generate ROS and undertake phagocytosis. Acute alcohol 
consumption leads to neutrophil imbalance in the liver releasing spontaneous NETs
[49]. The scavenging ability of macrophages to eliminate NETs diminishes resulting in 
persistent inflammation via hepatocyte damage[49]. During AH, the infiltration of 
neutrophils is believed to occur via the activation of KCs, which recruit cytokines and 
chemokines including IL-8 and IL-17. In mouse models, blockade of inflammatory 
mediators such as IL-8 and IL-17, which are necessary for neutrophil infiltration, can 
ameliorate liver disease[50,51], which supports neutrophil dysfunction in disease 
progression. Patients with ALD have a decreased baseline function of neutrophils in 
the liver[14], which may provide an explanation for high rates of bacterial, fungal and 
viral infection as well as organ failure and mortality. Neutrophil dysfunction has been 
shown to be reversed in patients with AH following endotoxin removal[52]. In AH 
patients, extensive modification of albumin occurs, further activating neutrophil infilt-
ration causing inflammation and oxidative stress[46,49]. Monocyte chemoattractant 
protein-1 also known as C–C motif chemokine ligand 2 is involved in proinflammatory 
cytokine activation and its levels have been found to be correlated with neutrophil 
infiltration and disease severity[46]. Therefore, neutrophils have been implicated in 
disease pathogenesis and a balance between anti-bacterial and anti-inflammatory 
functions is important for ALD patients.
Adaptive immunity
The adaptive immune response has also been implicated in pathogenesis of ALD 
(Figure 3). Early studies in both animals and humans have shown excessive alcohol 
consumption reduces peripheral T cell numbers, disrupts the balance between phe-
notypes, impairs function and promotes apoptosis[53]. Alcohol consumption can cause 
lymphopenia as well as disrupt the balance between T cell phenotypes, causing a shift 
from naïve populations to memory cells, experimentally and clinically[54-56]. Cy-
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Figure 3 Innate and adaptive immune response to alcohol exposure. Kupffer cells, hepatic stellate cells and natural killer cells are components of the 
innate immune system which becomes activated following chronic alcohol consumption. This leads to the release of inflammatory cytokines, causing further 
recruitment of inflammatory cells. The adaptive immune system also becomes activated releasing inflammatory mediators as well as antibody generation to protein 
and Malondialdehyde-acetaldehyde adducts. Both immune response mechanisms eventually become dysregulated over time with alcohol consumption. (Figure 
created with BioRender.com). HSC: Hepatic stellate cell; IFN-γ: Interferon-γ; IL: Interleukin; KC: Kupffer cell; LPS: Lipopolysaccharide; NK: Natural killer; NKT: 
Natural killer T; ROS: Reactive oxygen species; TGF-β: Transforming growth factor β; TLR4: Toll-like receptor 4; TNF-α: Tumor necrosis factor-α.
totoxic CD8+ T cells are greatly reduced, and this reduction was shown to correlate 
with stage of fibrosis and Child-Pugh (CTP) score, impairing cytotoxic functions 
leading to immune incompetence[56]. Decreased numbers of regulatory T cells are also 
associated with immune activation and increased inflammatory cytokines in AH[57].
More recently increasing phenotypes of T cells have been implicated in ALD. 
Chemokines such as CCL5, a chemoattractant for immune cells such as T lymphocytes, 
has been found to be upregulated in the liver[58]. Various proteins are expressed on 
the cell surface such as T-cell receptor, which recognize antigens and elicit a response. 
Infiltration and activation of both CD4+ and CD8+ T cells have been found to be 
increased in the livers of patients with ALD[58,59]. Until recently it had not been 
defined whether the increased activation of T cells in the livers of ALD patients were 
caused by bystander activation or due to an antigen-specific response[58,59]. Protein 
adducts derived from alcohol metabolism and lipid peroxidation have been identified 
in the liver of patients which act as neoantigens. These neoantigens are presented to 
CD4+ T cells by antigen presenting cells inducing proliferation[58,59]. As well as 
antigen-specific activation, bystander activation of T cells can occur induced in the 
absence of via cytokines, DAMPs and PAMPs[59]. This infiltration of T cells has been 
found to be correlated with inflammation and necrosis in ALD as well as regeneration. 
Therefore, both antigen-specific and bystander activation may contribute to the 
progression of ALD but also provide a beneficial role, however, this requires further 
research.
Alterations in regulatory cells may also provide an explanation for disease pa-
thogenesis, as oxidative stress is known to lower regulatory T cell populations in the 
liver[60]. Th17 cells have been identified in the livers of ALD patients and are critical 
for defense of bacterial infections[46]. These cells produce IL-17 and promote neu-
trophil infiltration. Mucosa-associated invariant T cells (MAIT), an innate-like subset 
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of T cells which inhibit bacterial infection, have been found to be reduced in ALD 
patients, consequentially increasing bacterial infection. Transcription factors (RORC/ 
RORγt, ZBTB16/PLZF and Eomes) which control the differentiation of MAIT cells 
were lower in AH patients compared to heathy controls[61]. Therefore, MAIT cell 
function may provide an important therapeutic approach for the treatment of ALD.
During ALD a loss of peripheral B cells also occurs, as well as increased amounts of 
circulating immunoglobulin[53]. B cell numbers are documented to be lower in heavy 
drinkers (90 to 249 drinks/mo) compared to moderate (30 to 89 drinks/mo) to light 
drinkers (< 9 drinks/mo) as well as a loss or circulating B cells in patients consuming 
164.9 to 400 g of alcohol/day on average. The differentiation of progenitor B cells can 
be affected by ethanol exposure via down-regulation of transcription factors (early B 
cell factor and Pax5) and cytokine receptors (IL-7R α)[62] and thus, alcohol use can 
affect subpopulations of B cells (B-1a, B-1b, B2-B)[53]. Exposure to 100 mmol/L of 
alcohol in vitro blocks the expression of transcription factors which has been shown to 
impair B cell differentiation[62]. Alcoholics cannot respond adequately to antigens 
which is likely due to a reduction in high-affinity antibody-producing B-2B subset[53]. 
Further, this decrease in B-2B subsets is typically associated with a decrease in the 
number of B-1a cells as well as a relative increase in the percentage of B-1b cells, 
important for T cell independent responses[53]. Although B cells numbers appear to be 
reduced in alcoholics, during cirrhosis, circulating levels of immunoglobulins (IgA, 
IgG, and IgE) may be increased against liver antigens. It has also been reported that 
IgG antibodies against CYP2E1 have developed in both alcohol fed rats and patients 
with advanced ALD[63]. The role of B cells in ALD requires further research.
DIAGNOSIS
Diagnosis of ALD is challenging as many patients present as asymptomatic. An ALD 
diagnosis is commonly made on a combination of clinical laboratory abnormalities, 
imaging and a history of alcohol abuse. Laboratory blood tests are used to identify 
abnormal aspartate aminotransferase (AST), alanine aminotransferase (ALT) level, 
gamma-glutamyl transpeptidase (GGT), mean corpuscular volume (MCV), carbohy-
drate-deficient transferrin (CDT) levels, albumin, prothrombin time (PT) (international 
normalized ratio), bilirubin and platelet counts. These blood tests are useful to suggest 
alcohol misuse but are inadequate at predicting alcohol use on their own or the disease 
severity[64]. Historically GGT was used alone as a marker for ALD, although elevated 
GGT alone has low sensitivity and specificity for alcohol abuse and may be limited by 
a high rate for false positives[64]. An AST/ALT ration above 2 is regarded as an 
indicator of ALD, although it is used less frequently to predict chronic alcohol abuse 
due to low sensitivity[64]. CDT is used as a biomarker for chronic ethanol intake (> 60 
g ethanol/d) and has a higher specificity (sensitivity 46%-73%, specificity 70%) than 
conventional markers such as GGT and MCV. However, no individual biomarker 
alone provides suitable sensitivity and specificity for ALD diagnosis, therefore, a 
combination of these biomarkers, imaging and in some cases a biopsy can provide an 
improved diagnosis.
CLINICAL STAGING OF DISEASE SEVERITY
There are various algorithms used to assess the severity of liver disease as well as 
predicating survival and treatment options (Table 1). The first models developed were 
the CTP score and the model for end-stage liver disease (MELD) score. The CTP score 
identifies patients as class A, B or C determined by serum levels of bilirubin and 
albumin, prothrombin time, ascites, and encephalopathy[65]. These measures are 
scored 1-3, with 3 being the most severe. A CTP defined as Class A (5-6 points) in-
dicates a 100% 1-year survival and 85% 2-year survival. Class B (7-9 points) has an 80% 
1-year survival and 60% 2-year survival. Class C (10-15 points) has a 45% 1-year 
survival and a 35% 2-year survival[66]. The MELD score is determined by total 
bilirubin, creatinine, and international normalized ratio (INR) levels, and is a widely 
useful tool for evaluation of liver transplantation in patients[67]. MELD is calculated 
by the formula 9.57 × loge (creatinine) + 3.78 × loge (total bilirubin) + 11.2 × loge (INR) 
+ 6.43[66]. Although these scores are useful in predicting mortality, they are less useful 
in assessing prognosis and treatment options. Research by Sheth et al[68] has shown 
that 30-d mortality predictions from the MELD scoring were 86% sensitive and 82% 
specific for MELD scores greater than 11[68].
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Table 1 Models for clinical staging in alcoholic liver disease
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INR: International normalized ratio.
The Maddrey Discriminant Function score (MDF) and The Glasgow AH Score 
(GAHS) were developed to determine disease severity and treatment options in AH 
patients. The MDF score assesses serum bilirubin and prothrombin time via the 
equation DF = {4.6 x [PT (sec) - control PT (sec)]} + (serum bilirubin) and classifies 
disease as either severe (MDF > 32) or non-severe (MDF < 32) and patients who fall in 
the severe category are most likely to benefit from steroid treatment[66]. The diag-
nostic sensitivity and specificity of the MDF scoring system was 86% and 48% when 
the DF was greater than 32[68]. The GAHS was developed to predict outcomes and to 
initiate therapy in AH patients. The GAHS includes age, white blood cell count, serum 
urea, bilirubin, and PT. Each variable is given a score and a final combined score 
between 5-12 is obtained. Patients with a GAHS above 9 have a poorer prognostic 
outcome. A study has shown patients with an MDF > 32 and a GAHS > 9 who were 
treated with steroids has a higher survival rate than those without treatment (59% 
compared to 38%)[67]. The Lille model is another prognostic model developed to 
identify response to corticosteroids in severe AH patients after 7 d of treatment[69]. 
Lille Model Score is defined as [exp(-R)]/[1 + exp(-R)]. Where r = 3.19 – 0.101*(age, 
years) + 0.147*(albumin day 0, g/L) + 0.0165* (evolution in bilirubin level, μmol/L) - 
0.206*(renal insufficiency) - 0.0065*(bilirubin day 0, μmol/L) - 0.0096*(PT, seconds)
[66]. It is useful for predicting short-term survival due to its high sensitivity and 
specificity and is able to identify patients at high risk of death at 6 mo[69].
THERAPEUTIC INTERVENTION
The consequences of excessive alcohol consumption causes significant morbidity and 
mortality with 704300 projected deaths due to alcohol-related liver disease in the 
United States between 2019-2040[9]. However, with a lack of new therapeutic options, 
abstinence is still regarded as the most important treatment, as well as treatments such 
as nutritional therapy, pharmacological therapy, combination therapy and transplan-
tation (Table 2).
Abstinence
Abstinence is the most important treatment for patients with ALD[70]. Abstinence 
from alcohol improves overall survival and prognosis as well as preventing further 
disease progression[71]. A reduction in portal pressure, decreased progression to 
cirrhosis and an improvement in survival has been shown after a period of abstinence
[70,72]. However, relapse rates are as high as 67%-81% in alcoholics[73]. Several drugs 
such as disulfiram, naltrexone and acamprosate have been trialed to sustain abstinence 
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Table 2 Current available treatments for alcoholic liver disease
Intervention Objective Treatment method Treatment effects
Abstinence Stop drinking Abstinence combined with disulfiram, 
naltrexone or acamprosate
Improve overall survival at all stages[70]. Acamprosate has been shown 





1.5 g protein and 35 to 49 kcal per kg of 
body weight. Supplementation with 
vitamins
Nutritional support showed improved hepatic encephalopathy and 
reduced infections in AH patients[80]
Corticosteroid Anti-
inflammatory
40 mg daily for 28 d, then 20 mg daily for 7 
d, and 10 mg daily for 7 d
Short-term histological improvement has been documented, however, 
no improvement in long term survival[83]
Pentoxifylline Anti-cytokine 400 mg orally three times a day for 4 wk Reduction in the levels of cytokines and lower mortality rate[86]
Infliximab Anti-cytokine Not confirmed. 5 mg/kg studied Further studies required. Treatment has shown to predispose patients 
to higher rate of infections as well as higher likelihood of mortality[93]
Liver 
transplantation
Surgery Healthy ‘donor’ liver transplanted. 6 mo 
abstinence required
Transplantation has been shown to improve in quality of life[95,96]
N-acetylcysteine Antioxidant Not confirmed In animal models NAC has been shown to prevent relapse and improve 
injury[111]. Further research is required
SAM Antioxidant Not confirmed SAM therapy has improved survival and delayed the need for 
transplants however other studies have not found evidence to support 
or refute its use[102,103]
Silymarin Herbal Eurosil 85® 420 mg a day Treatment with Silymarin reduced mortality and improved 4-yr overall 
survival in cirrhotic patients as well as improving liver function[119]
Betaine Nutrient Not confirmed Animal models have shown betaine supplementation can attenuate 
alcoholic fatty liver[106-108,120,121]
AH: Alcoholic hepatitis; NAC: N-acetylcysteine; SAM: S-adenosyl methionine.
and treat alcohol addiction. However, disulfiram has little evidence at improving 
abstinence[74]. Naltrexone, an opioid antagonist aimed to control alcohol cravings 
lowers the risk of relapse, although, it also has been shown to cause hepatocellular 
injury[71,75]. Acamprosate is used to minimize withdrawal symptoms when abstai-
ning from alcohol[76]. It has been shown to reduce withdrawal in 15 controlled trials
[77].
Nutritional therapy
Malnutrition is often correlated with disease severity in ALD patients[78]. Alcoholics 
suffer from deficiencies in several vitamins and minerals, including vitamin A, vitamin 
D, thiamine, folate, pyridoxine, and zinc[78]. Supplementation with zinc has shown to 
improve and prevent liver disease, as well as block mechanisms of liver injury 
including ‘leaky gut’, oxidative stress and apoptosis in animal models[79]. The 
recommended amount for ALD patients is 1.5 g of protein/kg body weight[2]. Supple-
mentation with micronutrients may be necessary if an individual develops deficien-
cies. Nutritional support in AH has been reported to improve hepatic encephalopathy 
and reduce infections[80]. A reverse in both energy and protein deficits has been 
shown reduce morbidity and mortality in patients with acute AH and cirrhosis[81].
Steroid and anti-cytokine therapy
Steroids serve as the primary treatment for severe AH[82]. Treatment with glucocor-
ticoids have decreased proinflammatory cytokines as well as inhibiting neutrophil 
activation[83]. Glucocorticoid therapy in AH patients showed short-term histological 
improvement and 28-d survival, however, long-term survival (beyond 1 year) was not 
improved[83].
Pentoxifylline, a phosphodiesterase inhibitor, is an anti-TNF-α agent. Pentoxifylline 
has been trialed in 101 patients with severe AH[84,85]. In-hospital mortality was 40% 
lower in those patients who were treated with pentoxifylline as well as reducing the 
likelihood of hepatorenal syndrome (HRS). 50% of deaths in the pentoxifylline 
treatment group were due to HRS, compared to 92% in the placebo group. Pentoxi-
fylline also exhibited a higher 6-mo survival and a reduced incidence of HRS in 
patients with severe AH[86].
The Steroids or Pentoxifylline for AH trial (double-blind, randomized control trial) 
has evaluated the effects of both treatment with prednisolone and/or pentoxifylline
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[87-89]. 1103 patients underwent randomization with 1053 suitable for primary end 
point analysis. The primary endpoint was mortality at 28 d[89]. Results showed 
primary end point mortality at 28 d was 17% in the placebo–placebo group, 14% in the 
prednisolone–placebo group, 19% in the pentoxifylline–placebo group, and 13% in the 
prednisolone–pentoxifylline group, showing that pentoxifylline did not improve 
patients overall survival[89]. Although not significant, the steroid group showed a 
trend toward reduced 28-d mortality[89]. However, in those patients who received 
steroid treatment the rate of serious infection was nearly doubled[89,90].
Another anti-cytokine therapy used in the treatment of ALD is infliximab, a mo-
noclonal chimeric anti-TNF antibody. In a primary randomized study using infli-
ximab, 20 AH patients were given either 5 mg/kg of infliximab as well as 40 mg/d of 
prednisone or prednisone alone[91]. The results indicated there was no change in 
overall mortality, however, combination therapy decreased cytokine levels[84]. In 
France, a clinical trial studied prednisolone (40 mg/d for 4 wk) treatment compared to 
prednisolone with infliximab (10 mg/kg, at study entry, 2 wk and 4 wk after entry) in 
36 patients[92]. Unfortunately the trial was stopped early due to mortality and in-
fection[84], and therefore, this study has received criticism for the dose of infliximab in 
the trial as this predisposed patients to infections[93]. These trials suggest that anti-
cytokine treatment in ALD is associated with an increase likelihood of severe in-
fections and mortality. Canakinumab, a licensed monoclonal antibody inhibitor of IL-1 
is currently being studied to treat ALD, as IL-1 has the ability to mediate disease 
progression in ALD[58].
Liver transplantation
Liver transplantation is a common treatment for end stage chronic liver disease; 
however, it remains controversial due to the increasing demand for donor organs as 
well as concerns of relapse from abstinence. Prior to surgery patients must abstain 
from alcohol for a fixed period of 6 mo[94]. Studies have shown patients who receive 
transplants have a better quality of life[95,96], however, less than 20% of patients 
whom have an end-stage liver disease receive surgery[97].
Antioxidants
Oxidative stress is a major contributor to the pathogenesis of chronic liver disease; 
therefore, antioxidant therapy has been considered to be beneficial in the treatment of 
ALD. Antioxidant agents able to mediate ROS include vitamins E and C, N-acetyl-
cysteine (NAC) as well as S-adenosyl methionine (SAM), and betaine.
SAM operates to synthesize glutathione, the primary cellular antioxidant[98,99]. 
Patients with AH and cirrhosis have decreased hepatic SAM levels[100]. In animal 
models, SAM supplementation can reverse liver injury and mitochondrial damage 
caused by alcohol[101]. However, no significant difference between SAM supple-
mentation and placebo groups has been reported[102,103]. Betaine, a nutrient involved 
in the formation of glutathione, is effective in protecting against damage from chronic 
alcohol consumption[104,105]. Supplementation with dietary betaine in animal studies 
has shown to ameliorate effects of oxidative stress[106-109]. In rats, NAC was able to 
reduce ethanol seeking behavior by 77%[110] as well as inhibiting ethanol intake by up 
to 70%[111]. In 174 patients with severe AH, combination therapy with NAC and 
prednisolone, compared to prednisolone only increased 1-mo survival in patients with 
AH, although 6-mo survival did not improve[112]. There are several trials underway 
investigating treatment options for ALD. A current clinical trial is assessing the effects 
of SAM and choline treatment for 24 wk against a placebo (trial number NCT 
03938662). Choline can help the liver undergo glucose metabolism as well as repairing 
the cell membrane[113]. As damaged livers cannot produce SAM sufficiently, adminis-
tration of choline and SAM may be a beneficial treatment in patients with ALD.
Fecal bacteria transplants
Chronic alcohol consumption leads to bacterial overgrowth promoting gut dysbiosis 
which correlates to disease severity. In cirrhosis patients Bacteroidetes and Firmicutes 
phyla were found to be decreased[114], however, Proteobacteria, Fusobacteria and 
Actinobacteria phyla were increased[114]. Cirrhosis is also characterized by reduced 
beneficial autochthonous bacteria such as Lachnospiraceae, Ruminococcaceae, and 
Clostridiales XIV as well increased pathogenic bacteria such as Enterococcaeae, Staphylo-
coccaceae and Enterobacteriaceae[115]. The significance of bacteria in liver disease has 
been demonstrated when ethanol-fed, germ-free mice developed severe inflammation 
and necrosis when supplemented with gut microbiota from AH patients[116]. Fur-
thermore, subsequent transfer of gut microbiota from patients without ALD, led to less 
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inflammation and liver injury[117] implicating the importance of healthy bacteria. 
More recently administration of probiotics containing beneficial bacteria such as 
Lactobacillus and Bifidobacterium to patients with ALD has improved liver damage and 
function, including reduction of ALT, AST and bilirubin[118]. Modulation of the gut 
microbiota with Profermin®, a disease specific food for special medical purposes, has 
been hypothesized to reduce disease progression (trial number NCT03863730). These 
studies provide strong evidence that fecal bacteria transplants/probiotic adminis-
tration may prove an effective mode for the treatment of ALD.
CONCLUSION
Previous research has uncovered many elements in the pathogenesis of ALD, how-
ever, the precise triggers and biochemical alterations are yet to be fully understood. 
Oxidative stress can impair proliferation and alter the immune system leading to 
bacterial overgrowth and an increased risk of infection. Poor treatments options are 
available for patients with ALD which have not transformed for several years. Treat-
ment options rely on abstinence, steroids, nutritional therapy and lastly liver trans-
plantation. Current new therapies are aimed at reducing pro-inflammatory signals as 
well as treating the gut-liver axis. This highlights a need for new therapeutic in-
tervention and advancements in the understanding of the mechanisms involved in 
disease pathogenesis.
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